Since receiving marketing authorisation in the UK, Europe and Australia, many hospitals and clinics have included CaRi-Heart in front-line cardiac care
CaRi-Heart is used by clinicians to detect patients’ coronary inflammation and plaque as well as to assess overall heart attack risk, so proper medical advice can be given and targeted treatment can be prescribed.
CCTA uses CT scan images to evaluate the presence of atherosclerotic plaque in the wall of the coronary arteries that causes narrowing of the artery lumen.
However, the presence of plaques, or narrowing caused by these plaques, does not correlate well with the future risk of heart attacks, with around two thirds of heart attacks occurring in patients with non-obstructive disease (Chan 2024, Lancet).
AI-enabled image analysis of the fat surrounding coronary arteries is a revolutionary technique that quantifies inflammation in the vessel.
CaRi-Heart® FAI-Score™ is the only commercially available tool that can detect and measure coronary inflammation on routine CCTA.
